5 results match your criteria: "Covance Clinical Research Unit AG[Affiliation]"
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
Alzheimers Dement (N Y)
November 2015
Probiodrug AG, Halle (Saale), Germany.
Article Synopsis
- Pyroglutamate-amyloid-β (pE-Aβ) peptides are linked to the development of Alzheimer's disease, and PQ912 is a drug that inhibits the enzyme responsible for their formation.
- A clinical trial tested PQ912's safety and effectiveness in both younger and older healthy subjects, finding it well tolerated and showing that drug exposure increased with higher doses.
- Results indicate that PQ912 could significantly inhibit the enzyme linked to Alzheimer’s, supporting its further development as a potential treatment for the disease.
Human pharmacokinetic profile of 1,25-dihydroxyvitamin D3-glycoside of herbal origin.
J Steroid Biochem Mol Biol
October 2014
Herbonis AG, Grellingerstrasse 33, P.O. Box CH-4000 Basel, Switzerland.
A natural form of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D, was identified in glycosylated form in Solanum glaucophyllum (SG). Solbone P, an extract of SG with high and homogenous content of glycosylated 1,25(OH)2D3, was chemically characterized and produced under GMP conditions. Three different doses of glycosylated 1,25(OH)2D3 were given as single oral dose to 16 healthy volunteers in a first-in-man trial.
View Article and Find Full Text PDFHumoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
Int Immunopharmacol
October 2013
Covance Clinical Research Unit AG, Allschwil, Basel, Switzeraland.
Antagonism of the chemokine receptor CXCR2 inhibits neutrophil trafficking and may thus be therapeutic in patients with chronic obstructive pulmonary disease and other lung disorders in which there is substantial infiltration by neutrophils. Here, we report the findings from a randomized, placebo-controlled, double-blind clinical trial of the small-molecule CXCR2 antagonist MK-7123 (formerly SCH 527123) that evaluated potential downstream effects of CXCR2 antagonism on immunogenic competency (B cell antibody response) in the adaptive immune system and delayed-type hypersensitivity (DTH) in healthy subjects (ages 34-65 years) dosed once daily for 30 days either with 30 mg MK-7123 (n=24) or placebo (n=7). Eligible subjects were seronegative for anti-hepatitis A virus (HAV) immunoglobulin G (IgG) and positive for DTH response to intradermal injection of Candida albicans antigen at screening.
View Article and Find Full Text PDFSafety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
Vaccine
January 2013
Covance Clinical Research Unit AG, SPC 327-10, Lettenweg 118, CH-4123 Allschwil, Switzerland.
Background: Pneumococcal vaccines based on conserved protein antigens have the potential to offer expanded protection against Streptococcus pneumoniae.
Objective: This study examined the safety and immunogenicity in adults of three doses of a pneumococcal single-antigen protein vaccine candidate formulated with aluminum hydroxide adjuvant and recombinantly derived, highly detoxified, genetically mutated pneumolysin protein (PlyD1).
Methods: This phase I, randomized, placebo-controlled, observer-blinded, dose-escalating study enrolled adults (18-50 years).
Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults.
Vaccine
December 2012
Covance Clinical Research Unit AG, Lettenweg 118, CH-4123 Allschwil, Switzerland.
Background: Pneumococcal vaccines based on conserved protein antigens have the potential to offer expanded protection against Streptococcus pneumoniae.
Objective: To explore safety and immunogenicity of a recombinant protein vaccine candidate against S. pneumoniae composed of adjuvanted pneumococcal histidine triad protein D (PhtD).